Table 2.

HR (male/female) for neonatal mortality for individual studies

Age category	NNIPS-3 (1999–2000) N=4127			CHX Study (2002–2006) N=23 644			NOMS (2010–2017) N=31 958
	HR (M/F)	95% CI	P value	HR (M/F)	95% CI	P value	HR (M/F)	95% CI	P value
Overall neonatal (0–28 days)	1.11	0.83 to 1.51	0.458	1.03	0.89 to 1.20	0.652	1.14	1.01 to 1.29	0.037
Early neonatal (0–7 days)	1.22	0.85 to 1.75	0.272	1.17	0.99 to 1.40	0.067	1.16	1.02 to 1.34	0.029
Late neonatal (7–28 days)	0.91	0.53 to 1.57	0.744	0.71	0.53 to 0.96	0.024	1.04	0.79 to 1.38	0.777
Subanalysis by days from birth
0–1 day	1.37	0.82 to 2.30	0.224	1.18	0.92 to 1.52	0.18	1.11	0.92 to 1.35	0.284
1–3 days	1.82	0.93 to 3.58	0.081	1.13	0.84 to 1.52	0.415	1.16	0.90 to 1.50	0.247
3–7 days	0.49	0.21 to 1.16	0.105	1.22	0.82 to 1.81	0.316	1.35	0.98 to 1.89	0.068
7–14 days	0.91	0.43 to 0.95	0.819	0.85	0.55 to 1.32	0.482	1.08	0.70 to 1.68	0.705
14–21 days	1.23	0.49 to 3.12	0.658	0.68	0.41 to 1.13	0.135	1.33	0.86 to 2.10	0.198
21–28 days	0.39	0.08 to 2.03	0.267	0.49	0.24 to 0.98	0.046	0.51	0.25 to 1.04	0.063

CHX, Chlorhexidine Study; NNIPS, Nepal Nutrition Intervention Project Sarlahi; NOMS, Nepal Oil Massage Study.